Is Zom a good stock to buy?
Jun 04, 2021 · Jun. 4 2021, Published 11:11 a.m. ET. Zomedica (ZOM) stock moved above the $1 level after a month on June 3. However, the stock couldn't hold on to that price level and eventually closed below $1...
How much of zomedica's stock are insiders buying and selling?
Apr 24, 2022 · Zomedica's stock was trading at $0.2078 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZOM shares have increased by 15.5% and is now trading at $0.24. View which stocks have been most impacted by COVID-19.
Is Zom a meme stock?
May 10, 2022 · ZOM Zomedica Corp — Stock Price and Discussion | Stocktwits. Zomedica Corp NYSEMkt Updated May 10, 2022 12:15 PM. ZOM 0.21 0.03 (12.88%) Pre-Market 0.01 (2.77%) 130,583. Key Data. 52wk Low 0.23. 52wk High 1.06. Mkt Cap 235.18m.
Is zomedica too risky to go short?
Feb 11, 2021 · How? As of Jan. 15, short interest in ZOM stock wasn’t that high (12.8%). But, as it zooms past the $2 price level, more bears may be willing to bet against it.
Will ZOM stock ever go up?
What will ZOM stock be worth?
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +475.82% increase from the last price of 0.21.
Is ZOM a strong buy?
Is Zomedica a good long-term investment?
How many shares of ZOM are there?
| Avg Vol (3 month) 3 | 18.43M |
|---|---|
| Shares Outstanding 5 | 979.9M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 965.89M |
| % Held by Insiders 1 | 2.56% |
Why is ZOM dropping?
Is ZOM undervalued?
What does ZOM company do?
Is ZOM a buy Zacks?
...
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.97% |
| 2 | Buy | 18.45% |
| 3 | Hold | 10.03% |
| 4 | Sell | 5.70% |
How has Zomedica's stock been impacted by COVID-19 (Coronavirus)?
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organ...
When is Zomedica's next earnings date?
Zomedica is scheduled to release its next quarterly earnings announcement on Tuesday, May 10th 2022. View our earnings forecast for Zomedica .
How were Zomedica's earnings last quarter?
Zomedica Corp. (NYSEAMERICAN:ZOM) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per shar...
What guidance has Zomedica issued on next quarter's earnings?
Zomedica issued an update on its FY 2021 earnings guidance on Monday, March, 14th. The company provided earnings per share (EPS) guidance of for th...
Who are Zomedica's key executives?
Zomedica's management team includes the following people: Mr. Robert Cohen , CEO & Director (Age 63, Pay $412.79k) Ms. Ann Marie Cotter CPA , C...
Who are some of Zomedica's key competitors?
Some companies that are related to Zomedica include Protagonist Therapeutics (PTGX) , Keros Therapeutics (KROS) , Myovant Sciences (MYOV) , Axs...
What is Zomedica's stock symbol?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
Who are Zomedica's major shareholders?
Zomedica's stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (2.93%), BlackR...
Which institutional investors are selling Zomedica stock?
ZOM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Commonwealt...
What is the P/E ratio of Zomedica?
The P/E ratio of Zomedica is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Where does Zomedica trade?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
What is Zomedica Corp?
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Is there enough data for Zomedica?
There is not enough analysis data for Zomedica.
Does Zomedica pay dividends?
Zomedica does not currently pay a dividend.
ZOM Stock: Upcoming Catalysts Do Not Justify Its Strong Performance
Zomedica shares were already up substantially before the recent move from $1 to $2 per share. Now up more than thirty-fold, why do shares keep on climbing? It’s simple. Those who didn’t buy in early are kicking themselves.
Why It Could Be Déjà Vu All Over Again
In January, many heavily shorted stocks headed to the moon. But, as February plays out, many of these are heading back down to earth. However, while the short-squeeze trade is fading, this name could see some benefit from a retail investor-fueled squeeze.
Bottom Line: Be Careful, Even if Shares Pull Back
Zomedica may be too risky at today’s $2.50 per share. But, is ZOM stock a worthwhile opportunity if it pulls back to near $1 per share? Not so fast. For sure, the company is worth more now than it was just a few months ago. The commercialization of Truforma and other products will likely result in improved results for its top and bottom line.
Zom Stock News
The earnings report of 25 February 2022 will constitute a ZOM stock news of interest. The only significant news of note after the retirement of erstwhile CEO Robert Cohen back in October 2021 was the recent press conference by the new CEO, which provided an update on the progress of new diagnostic assay developments.
Will Zom Stock Go Up?
Zomedica’s share price has been in a slump for the major part of 2021.
Zom Stock Forecast 2022
What is the Zom stock forecast for 2022? The Zom stock forecast 2022 is a medium-term forecast that aims to predict the Zom stock price in the next few months. Following the completion of the double top on the weekly chart, price action is now trading around the measured move’s completion zone.
Zom Stock Forecast 2025
The Zom stock forecast 2025 retains the bearish outlook that has permeated the stock for the latter part of 2021. There aren’t positive fundamentals to suggest a change in sentiment. Any rallies would be purely speculative and would only provide opportunities for traders looking to make huge gains by shorting the stock.
ZOM: Monthly Chart
The monthly chart shows that the RSI still has room to head into the oversold region, while there is a lack of good buying volume. Indeed, trading volumes are fragile. The current support at 0.3048 remains the only factor holding price activity from declining further.
Zom Stock forecast 2030
If you have a long term view and want to get some insight via the Zom stock forecast 2025, then this is where it gets interesting. CEO Larry Heaton recently delivered an address where he outlined the company’s strategy for driving sales of Truforma. This is to be based on three pillars:
Is Zom a Good Stock to Buy
ZOM stock could provide some good gains in the long term if its veterinary diagnostic and therapeutic technologies can gain sufficient market traction. However, the stock remains a speculative investment that owed its previous tops to the Reddit meme that lifted other stocks like GameStop and AMC.
What is the best platform to buy Zomedica?
We recommend using eToro if you are looking to buy Zomedica stock. eToro offers 0% commission trading and fractional investing, making the platform ideal for stock trading.
What is Zomedica Corp?
Zomedica Corp. (ZOM) is a veterinary health company based in Ann Arbor that develops and markets point-of-care diagnostics. These products and services refer to the process of identifying medical issues in companion animals in real-time, which is much faster than the current process allows, meaning animals can be treated more efficiently. This looks to be a lucrative market for ZOM, as the amount of people with companion animals has skyrocketed since the COVID-19 pandemic.
How much does eToro take?
eToro accepts deposits from as little as $50, with deposits entirely free to make. In terms of methods, eToro accepts funding from the following:
What is Zomedica Pharmaceuticals?
Zomedica Pharmaceuticals is a veterinary health company that produces point-of-care diagnostic devices for veterinarians. Zomedica has just begun selling their TRUFORM device in March 2021, so revenues have only started rolling in within the past seven months.
What is Zomedica's business model?
One exciting aspect of Zomedica’s business model is that the company has changed to a ‘direct to consumer’ approach. This cuts out the distributor, meaning that Zomedica can really begin ramping up its marketing and increase hype about the product. Ultimately, once more devices are added to Zomedica’s portfolio, this direct selling method will offer them more control over pricing, meaning larger revenues in the future.
Is Zom a penny stock?
As such, ZOM is seen as more of a ‘penny stock’ by most analysts on Wall Street.
Is ZOM a small cap stock?
As noted, due to ZOM being a small-cap stock, it is much riskier than buying an established stock. However, this provides the opportunity for more significant gains, so it’s worth considering this in your decision.
How much is Zomedica stock worth in 2021?
The Zomedica Pharmaceuticals Corp stock price gained 3.73% on the last trading day (Friday, 9th Jul 2021), rising from $0.71 to $0.74. During the day the stock fluctuated 4.11% from a day low at $0.72 to a day high of $0.75. The price has fallen in 6 of the last 10 days and is down by -12.33% for this period. Volume fell on the last day by -6 million shares and in total, 18 million shares were bought and sold for approximately $13.09 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Is Zomedica Pharmaceuticals Corp a negative stock?
Zomedica Pharmaceuticals Corp holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.
A Closer Look at ZOM Stock
A year ago, the situation of Zomedica’s investors was much better than it is today. Amazingly, ZOM stock shot up from 10 cents in late 2020 to a 52-week high of $2.91 on Feb. 8, 2021.
First, the Bad News
Now I’m not going to sugarcoat the value proposition of Zomedica. It’s a small company with lackluster financials, to put it politely.
A Shocking Discovery
What was this acquisition? That is the billion-dollar question for Zomedica’s stakeholders.
The Bottom Line
Make no mistake about it: the acquisition of PulseVet is a major gamble for Zomedica. Only time will tell whether sound-wave technology will be widely accepted by veterinarians and pet owners.
This One Thing Will Boost ZOM Stock
Whenever I read the words “one thing,” I always go back to the movie City Slickers when Curly — played by Jack Palance — tells Mitch — played by Billy Crystal — the secret of life.
Cash in the Bank Helps a Lot
If you look at Zomedica’s Q1 2021 10-Q, it isn’t the 18,380.1% increase in cash and cash equivalents during the quarter that jumps out at me. It is the 21.4% increase in cash flows used in operating activities during the quarter.
Bottom Line on ZOM Stock
I’m far from abandoning Zomedica as my favorite penny stock. However, I’ll be watching the company’s every move throughout the remainder of 2021.
